While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

An open letter signed by more than 50 industry executives blasts a “fundamentally, fatally flawed” report that urges greater ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma ...

As an office of the executive branch, the Department of Health and Human Services “does not have the authority” to implement ...